Clinical trial · Observational
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. The main questions it aims to answer are: * Are there T cells in the bone marrow that can recognize MPN cells? * Which targets (antigens) on MPN cells are recognized by these immune cells? * Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies? Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison. By providing blood and bone marrow samples, participants will: * Allow researchers to study immune cells and genetic material from these samples * Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN. Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia (ET) | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.85 |
| Myeloproliferative Neoplasm (MPN) | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Polycytemia Vera | — | UNRESOLVED | — |
| Primary Myelofibrosis (PMF) | Primary Myelofibrosis | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identification of MPN-specific CD8+ T cell clonotypes and corresponding tumor antigens
- timeFrame
- Throughout the whole study, approximately during 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. * Patients not previously diagnosed with a haematological disease as controls Exclusion Criteria: * Patients with any other hematological malignancy.
References
Publications (0)
Data not yet available